Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating Expenses:
Research and development	$ 3,029	$ 3,004	$ 6,346	$ 8,030
General and administrative	2,321	2,068	7,353	6,980
Total operating expenses	5,350	5,072	13,699	15,010
Operating loss	(5,350)	(5,072)	(13,699)	(15,010)
Other income:
Investment income, net	25	175	118	611
Total other income	25	175	118	611
Net loss before benefit from income taxes and noncontrolling interests	(5,325)	(4,897)	(13,581)	(14,399)
Benefit from income taxes	0	0	(10,872)	0
Net loss	(5,325)	(4,897)	(2,709)	(14,399)
Less - net income attributable to noncontrolling interests	2	1	10	6
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (5,327)	$ (4,898)	$ (2,719)	$ (14,405)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.29)	$ (0.47)	$ (0.19)	$ (1.40)
Weighted average common shares outstanding
Basic and diluted shares	18,597	10,411	14,116	10,279